EGFR and neoplasm: An early-phase study of CARv3-TEAM-E T cell therapy demonstrated significant tumor regression in patients with glioblastoma, supporting EGFR (including the EGFR variant III and wild-type EGFR) as a promising immunotherapeutic target in glioblastoma.29